| Dr Richard W Graham, MD | |
|
108 N Main St, White River Junction, VT 05001-7056 | |
| (802) 296-7370 | |
| (802) 296-7174 |
| Full Name | Dr Richard W Graham |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 45 Years |
| Location | 108 N Main St, White River Junction, Vermont |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225092794 | NPI | - | NPPES |
| 1225092794 | Medicaid | VA | |
| 24388 | Other | VA | ALLIANCE |
| 32000393 | Medicaid | NH | |
| 59294 | Other | VA | SOUTHERN HEALTH |
| 2582 | Other | VA | CIGNA |
| 340001591 | Other | VA | RAILROAD MEDICARE |
| 447989 | Other | VA | SOUTHERN HEALTH EFF111506 |
| 45722 | Other | VA | SENTARA FAMILY CARE |
| 1900011 | Other | VA | UNITED HEALTHCARE |
| 36538 | Other | VA | CARENET |
| 3762531 | Other | VA | AETNA HMO |
| 4063408 | Other | VA | AETNA PPO |
| 497602109 | Other | VA | TRICARE |
| 247815 | Other | VA | ANTHEM BCBS |
| 3016615 | Other | VT | MVP |
| 002130301 | Other | MEDICARE PTAN | |
| 1478176 | Other | VT | CIGNA |
| 1018994 | Medicaid | VT | |
| 642070000-00 | Other | VA | QUALCHOICE |
| 66241 | Other | VA | CARENET EFF 111506 |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 0101 033452 (Virginia) | Secondary |
| 208800000X | Urology | 042-0012170 (Vermont) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Southside Regional Medical Center | Petersburg, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bon Secours Medical Group Richmond Specialty Care Llc | 8022440056 | 260 |
News Archive
Given that epilepsy impacts more than 2 million Americans, there is a pressing need for new therapies to prevent this disabling neurological disorder. New findings from the neuroscience laboratory of Mark S. Shapiro, Ph.D., at The University of Texas Health Science Center at San Antonio, published Dec. 20 in the high-impact scientific journal, Neuron, may provide hope.
In honor of National Cholesterol Education Month, Hotze Health & Wellness Center (HHWC) is encouraging both men and women to take a proactive role in healthy aging, specifically heart disease prevention. HHWC is advocating effective measures to prevent heart attacks and is shedding new light on cholesterol myths and the dangers of cholesterol-lowering (statin) drugs.
BioCryst Pharmaceuticals, Inc. today announced that its partner, Shionogi & Co., Ltd. has filed a New Drug Application (NDA) in Japan to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza. As a consequence of this filing, BioCryst will receive a regulatory milestone payment of $7 million under its agreement with Shionogi.
XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study using a True Human monoclonal antibody (MABp1) in patients with type 2 diabetes. Results from this study continue to reinforce the role of IL-1α as a master regulator of chronic inflammation in multiple disease states, and the therapeutic benefits of neutralizing antibodies produced from the XBiotech platform.
› Verified 4 days ago
| Entity Name | Bon Secours Medical Group Richmond Specialty Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477112225 PECOS PAC ID: 8022440056 Enrollment ID: O20191113002170 |
News Archive
Given that epilepsy impacts more than 2 million Americans, there is a pressing need for new therapies to prevent this disabling neurological disorder. New findings from the neuroscience laboratory of Mark S. Shapiro, Ph.D., at The University of Texas Health Science Center at San Antonio, published Dec. 20 in the high-impact scientific journal, Neuron, may provide hope.
In honor of National Cholesterol Education Month, Hotze Health & Wellness Center (HHWC) is encouraging both men and women to take a proactive role in healthy aging, specifically heart disease prevention. HHWC is advocating effective measures to prevent heart attacks and is shedding new light on cholesterol myths and the dangers of cholesterol-lowering (statin) drugs.
BioCryst Pharmaceuticals, Inc. today announced that its partner, Shionogi & Co., Ltd. has filed a New Drug Application (NDA) in Japan to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza. As a consequence of this filing, BioCryst will receive a regulatory milestone payment of $7 million under its agreement with Shionogi.
XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study using a True Human monoclonal antibody (MABp1) in patients with type 2 diabetes. Results from this study continue to reinforce the role of IL-1α as a master regulator of chronic inflammation in multiple disease states, and the therapeutic benefits of neutralizing antibodies produced from the XBiotech platform.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Richard W Graham, MD 44 S Main St, Randolph, VT 05060-1381 Ph: (802) 728-2372 | Dr Richard W Graham, MD 108 N Main St, White River Junction, VT 05001-7056 Ph: (802) 296-7370 |
News Archive
Given that epilepsy impacts more than 2 million Americans, there is a pressing need for new therapies to prevent this disabling neurological disorder. New findings from the neuroscience laboratory of Mark S. Shapiro, Ph.D., at The University of Texas Health Science Center at San Antonio, published Dec. 20 in the high-impact scientific journal, Neuron, may provide hope.
In honor of National Cholesterol Education Month, Hotze Health & Wellness Center (HHWC) is encouraging both men and women to take a proactive role in healthy aging, specifically heart disease prevention. HHWC is advocating effective measures to prevent heart attacks and is shedding new light on cholesterol myths and the dangers of cholesterol-lowering (statin) drugs.
BioCryst Pharmaceuticals, Inc. today announced that its partner, Shionogi & Co., Ltd. has filed a New Drug Application (NDA) in Japan to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza. As a consequence of this filing, BioCryst will receive a regulatory milestone payment of $7 million under its agreement with Shionogi.
XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study using a True Human monoclonal antibody (MABp1) in patients with type 2 diabetes. Results from this study continue to reinforce the role of IL-1α as a master regulator of chronic inflammation in multiple disease states, and the therapeutic benefits of neutralizing antibodies produced from the XBiotech platform.
› Verified 4 days ago
Dr. Florian Rudolf Schroeck, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 215 N Main St, White River Junction, VT 05009 Phone: 802-295-9363 | |
Rodney J Taylor, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: Va Medical Ctr, 215 North Main Street, White River Junction, VT 05009 Phone: 802-295-9363 Fax: 802-291-6262 |